All News

Pharmacists were asked about their perceived knowledge and attitudes toward patients with Down syndrome.

The autoinjector cuts administration to under 10 seconds, offering patients an at-home option for fluid overload in heart failure and chronic kidney disease.

A new survey shows widespread uncertainty about which vaccines the CDC recommends during pregnancy, underscoring the counseling role pharmacists play.

In the first of a 2-day hearing on peptide therapy access, the FDA votes in favor of approving 4 of the products discussed, with the potential for more on Friday.

Experts collaborate on the best approaches for boosting immunization rates in populations across school campuses and shared living facilities.

As the pharmacist’s role continues to expand throughout health care, they are now being challenged to step in as opioid stewards in a rapidly evolving pain management landscape.

Through pharmacists’ statewide billing capabilities, researchers explore how educational support impacts community pharmacies’ medical billing.

New policies urge pharmacists to identify disinformation and seek legal protection against AI-generated impersonation.

Detailed results show the investigational islatravir/lenacapavir combination sustained virologic suppression as a potential once weekly HIV treatment.

In part 2, Richard Dion, PharmD, addresses some of the persistent challenges among hospital pharmacies and their pain management models, offering some expert solutions to move forward.

This episode explores PBMs’ copay collection discrepancies and how improper documentation can be the downfall for pharmacy business.

Pharmacists and other clinicians counseling postpartum patients may find more success with meal-timing strategies that require minimal disruption to routines.

A new report on glucagon-like peptide-1 receptor agonists for obesity finds real clinical value alongside budget impact that already exceeds the review's own threshold.

Immunology expert Paul Licciardi, PhD, weighs in on the current state of recommended pneumococcal vaccines and what is on the horizon in the developmental stage.

Vaccine guidance in the US is undergoing a dramatic change, leaving pharmacists uncertain about coverage, authority, and flu-season timing.

In part 2, Paul Licciardi, PhD, dives into the evolving need for updated pneumococcal vaccine recommendations and how pharmacists can keep their patients informed.

A secret shopper study finds most are still compounding semaglutide and tirzepatide with additives, often through suppliers lacking sterile compounding licenses.

Richard Dion, PharmD, joins to discuss the growing prominence of opioid stewardship and where the pharmacist can assist in patient programming.

Analyzing nearly a decade of pharmaceutical interventions in community pharmacies, researchers reveal the role pharmacists play in self-medication.

Bivalent mRNA and protein-based fourth doses produce comparable protection against Omicron JN.1 infection over 12 months.

In part 1 of our interview with Paul Licciardi, PhD, he addresses the lowered pneumococcal vaccination age as well as the adult population’s overall relationship with immunization.

Pharmacist credentialing unlocks payer contracts and boosts reimbursement and can help avoid risky third-party billing as clinical services expand.

With calls to expand access across the health care ecosystem, researchers explore pharmacists' perceptions regarding independent prescribing.

A rapidly growing multistate cyclosporiasis outbreak has pushed national case counts to nearly 7000.

With the Medicare GLP-1 Bridge Program just 2 weeks old, a drug market expert shared their thoughts on what the initiative may mean for pharmacists and their patients.

Nine pharmacy organizations state that the revised charter overemphasizes vaccine risk and could delay recommendations pharmacists rely on for scope of practice and insurance coverage.

Among adult patients who have reported a case of invasive pneumococcal disease, researchers address the association of risk factors and recurrent disease.

Lipfendra (enlicitide) showed placebo-adjusted low-density lipoprotein cholesterol reductions of more than 50% in 2 phase 3 trials.